Osteoporosis was the underlying cause of most of these injuries. White women 65 or older have twice the incidence of fractures as African-American women. Alendronate is approved for treatment of glucocorticoid-induced osteoporosis in men and women. Risedronate is approved for prevention and treatment of glucocorticoid-induced osteoporosis in men and women. Treatments under investigation include sodium fluoride, vitamin D metabolites, parathyroid hormone, and other bisphosphonates and SERMs.
Medical experts agree that osteoporosis is highly preventable.
However, if the toll of osteoporosis is to be reduced, the commitment to osteoporosis research must be significantly increased. It is reasonable to project that with increased research, the future for definitive treatment and prevention of osteoporosis is very bright. The National Resource Center is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases with contributions from the National Institute of Child Health and Human Development, National Institute of Dental and Craniofacial Research, National Institute of Environmental Health Sciences, NIH Office of Research on Women's Health, Office of Women's Health, PHS, and the National Institute on Aging. The Resource Center is operated by the National Osteoporosis Foundation, in collaboration with The Paget Foundation and the Osteogenesis Imperfecta Foundation.